601607 上海医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.9087.7596.4945.5589.650
总资产报酬率 ROA (%)1.9302.5202.1021.8383.107
投入资产回报率 ROIC (%)3.2454.1943.5483.1465.510

边际利润分析
销售毛利率 (%)10.52410.72611.12912.03613.142
营业利润率 (%)3.3963.5062.9582.9463.886
息税前利润/营业总收入 (%)3.8443.9593.4523.2814.363
净利润/营业总收入 (%)2.5862.4592.1331.9853.014

收益指标分析
经营活动净收益/利润总额(%)87.22774.30094.447103.28880.311
价值变动净收益/利润总额(%)14.21335.6657.2854.7728.536
营业外收支净额/利润总额(%)-0.214-1.245-1.505-8.689-2.342

偿债能力分析
流动比率 (X)1.3471.3351.3631.3271.351
速动比率 (X)1.0380.9991.0541.0281.039
资产负债率 (%)61.19561.48962.14362.10560.632
带息债务/全部投入资本 (%)41.08743.27443.46742.10339.011
股东权益/带息债务 (%)136.089124.633124.672130.853149.257
股东权益/负债合计 (%)53.56752.93752.14052.05255.824
利息保障倍数 (X)8.4507.9786.4165.7487.708

营运能力分析
应收账款周转天数 (天)107.065102.47099.44196.60196.888
存货周转天数 (天)60.05059.94055.60555.88254.997